*Data from the Phase 3 ADVANCE trial.
Significant 54% reduction in monthly mean migraine days vs 33% for placebo1,2
Similar results were seen in the Phase 2b/3 dose-finding study
With the majority of impact observed within Weeks 1-41,3
Over 60% of patients cut their migraine days by at least half vs 29% for placebo1
*Data from the Phase 3 ADVANCE trial.
QULIPTA® (atogepant) is indicated for the preventive treatment of episodic migraine in adults.
The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.
Strong CYP3A4 Inhibitors: 10 mg once daily.
Strong and Moderate CYP3A4 Inducers: 30 mg or 60 mg once daily.
OATP Inhibitors: 10 mg or 30 mg once daily.
Severe Renal Impairment or End-Stage Renal Disease: 10 mg once daily.
Avoid use in patients with severe hepatic impairment.
US-QLP-220116
The most common adverse reactions (≥5% and at least twice the rate of placebo) are nausea and constipation.
Please see full Prescribing Information.
Please see full Prescribing Information.
